Petrelli F, Grizzi G, Ghidini M, et al. - In order to evaluate the outcome for cancer patients managed with immune checkpoint inhibitors (ICIs) who develop immune-related adverse events (irAEs), researchers conducted a systematic review and meta-analysis, analyzing the relevant published literature. They explored PubMed, EMBASE, and the Cochrane Library database from their inception to November 2018, to identify prospective or retrospective studies. They analyzed 30 studies with 4,324 patients treated with ICIs. Reduced risk of death was observed in patients who developed irAEs. Similarly, a decreased risk of progression was noted in relation to the occurrence of irAEs. The odds of response were identified to be 4.56. Survival and response in patients treated with ICIs were predicted by irAEs. Although this correlation cannot be completely explained, it may be associated with the strongest T-cell activation.